There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Humanigen (HGEN) and InMode (INMD) with bullish sentiments.
Humanigen (HGEN)
In a report released today, Joseph Pantginis from H.C. Wainwright initiated coverage with a Buy rating on Humanigen and a price target of $31.00. The company’s shares closed last Tuesday at $12.03.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 25.8% and a 56.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Humanigen is a Moderate Buy with an average price target of $31.00.
See today’s analyst top recommended stocks >>
InMode (INMD)
Canaccord Genuity analyst Kyle Rose maintained a Buy rating on InMode yesterday and set a price target of $42.00. The company’s shares closed last Tuesday at $41.69.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 10.8% and a 52.3% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for InMode with a $44.50 average price target, implying a 3.8% upside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $55.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.